Subtype‐Dependent Response of Hepatitis B Virus during the Early Phase of Lamivudine Treatment

Open Access

1 May 2002

journal article
clinical trial
Published by Oxford University Press (OUP) in Clinical Infectious Diseases

Vol. 34 (9) , 1273-1277
https://doi.org/10.1086/339959

Abstract

We conducted a 12-month longitudinal investigation of the subtype-dependent response of hepatitis B virus (HBV) to lamivudine treatment in 43 consecutive patients with chronic hepatitis B. HBV subtype ayw appears to respond better to lamivudine monotherapy than does HBV subtype adw (P = .005). This might be the reason for the lower incidence of lamivudine-resistant strains observed in persons infected with HBV subtype ayw during follow-up.

Keywords

This publication has 18 references indexed in Scilit:

Extended Lamivudine Treatment in Patients With Chronic Hepatitis B Enhances Hepatitis B E Antigen Seroconversion Rates: Results After 3 Years of Therapy
Hepatology, 2001
20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw
The Lancet, 2001
Long-term therapy of chronic hepatitis B with lamivudine
Hepatology, 2000
High-Throughput Quantitative Analysis of Hepatitis B Virus DNA in Serum Using the TaqMan Fluorogenic Detection System
Hepatology, 2000
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
Gastroenterology, 2000
Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial
Gut, 2000
Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States
New England Journal of Medicine, 1999
A One-Year Trial of Lamivudine for Chronic Hepatitis B
New England Journal of Medicine, 1998
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
Hepatology, 1998
Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains
Journal of General Virology, 1992